Clinical aspects of TNBC include high invasive potential, susceptibility to recurrence, the poorest prognosis among all BC subtypes and limited treatment options [27,30,31] as the lack of ERs, PRs, and HER2 expression leads to insensitivity of TNBC tumors to hormonal or HER2-targeted therapies [30]. The gene discussed is WNK3; the disease is breast cancer.